ROMK Inhibitors for Selective Diuresis Without Metabolic Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertension and conditions related to excessive salt and water retention lack effective diuretic and natriuretic agents with reduced side effects, such as hypo- or hyperkalemia, new onset of diabetes, and dyslipidemia.
Innovation Solution
Development of compounds that selectively inhibit the Renal Outer Medullary Potassium (ROMK) channel, acting as diuretics and natriuretics to manage hypertension and related conditions by increasing urine volume and preventing sodium reabsorption in the kidneys.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diuretic agents are used to treat hypertension and salt/water retention, then blood pressure is reduced, but side effects such as hypo- or hyperkalemia, new onset of diabetes, and dyslipidemia occur
Solution Approach 1:
The patent changes the molecular target parameter from conventional diuretic targets to the ROMK potassium channel. By selecting a different physiological target (ROMK channel in the kidney), the invention achieves diuretic efficacy through a novel mechanism that avoids the metabolic side effects associated with traditional diuretics, thus resolving the contradiction between therapeutic efficacy and side effect profile
Solution Approach 2:
The invention extracts and isolates the specific function of the ROMK channel in potassium recycling and sodium-potassium coupling from the complex renal transport system. By targeting this single channel rather than broad diuretic mechanisms, the patent achieves selective inhibition that provides therapeutic benefit without triggering the systemic metabolic disturbances (diabetes, dyslipidemia, electrolyte imbalances) caused by conventional agents
2Object-affected harmful factors
If ROMK channel inhibitors are developed to act as novel diuretics, then side effects are reduced, but the complexity of drug development increases
Solution Approach 1:
The patent uses high-throughput screening as an intermediary methodology to bridge the gap between novel ROMK channel target identification and drug discovery. This systematic screening approach simplifies the complex development process by providing a standardized, high-efficiency method to identify and validate potential inhibitors, thus reducing the overall complexity despite targeting a novel mechanism
3Object-affected harmful factors
If selective ROMK channel inhibitors are used, then diuretic efficacy is achieved with reduced metabolic side effects, but selectivity and specificity must be precisely controlled
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular characteristics that confer selectivity for the ROMK channel over other potassium channels and renal transporters. The screening process identifies compounds with particular structural features (local molecular properties) that enable selective binding to ROMK, ensuring the drug acts only on the intended target and achieves the desired metabolic profile without off-target effects
Data Source
AI summary
This invention relates to compounds having structural Formula I:and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.